Genmab A (GMAB) Gross Profit (2024 - 2026)

Genmab A has reported Gross Profit for 3 years, with the latest figure at $831.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 23.48% year-over-year to $831.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 billion (up 20.17% YoY), and the FY2025 full-year result was $3.5 billion, up 16.92% from the prior year.
• Gross Profit for Q1 2026 stood at $831.0 million, down from $964.0 million in the prior quarter.
• The five-year high for Gross Profit was $964.0 million in Q3 2025, with the low at $576.0 million in Q1 2024.
• Historically, Gross Profit has averaged $777.0 million across 3 years, with a median of $776.0 million in 2024.
• The largest YoY upside for Gross Profit was 24.23% in 2025 against a maximum downside of 15.58% in 2025.
• Genmab A's Gross Profit stood at $776.0 million in 2024, then gained by 24.23% to $964.0 million in 2025, then retreated by 13.8% to $831.0 million in 2026.
• The last three Gross Profit figures came in at $831.0 million (Q1 2026), $964.0 million (Q3 2025), and $868.0 million (Q2 2025), per Business Quant data.